Tags

Type your tag names separated by a space and hit enter

Experience with pneumococcal conjugate vaccine in Norway.
Expert Rev Vaccines. 2009 Feb; 8(2):159-65.ER

Abstract

Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced into the Norwegian childhood vaccination program in July 2006 in a 2+1 dose (three-dose) schedule. Vaccine coverage quickly reached high levels and the incidence rate of invasive pneumococcal disease in children under 2 years of age declined rapidly. The vaccine program's effectiveness was estimated to be 74%.

Authors+Show Affiliations

Department Director, Department of Bacteriology & Immunology, Division of Infectious Disease Control, Norwegian Institute of Public Health, PO Box 4404, Nydalen, NO-0403 Oslo, Norway. ingeborg.aaberge@fhi.no

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19196196

Citation

Aaberge, Ingeborg S.. "Experience With Pneumococcal Conjugate Vaccine in Norway." Expert Review of Vaccines, vol. 8, no. 2, 2009, pp. 159-65.
Aaberge IS. Experience with pneumococcal conjugate vaccine in Norway. Expert Rev Vaccines. 2009;8(2):159-65.
Aaberge, I. S. (2009). Experience with pneumococcal conjugate vaccine in Norway. Expert Review of Vaccines, 8(2), 159-65. https://doi.org/10.1586/14760584.8.2.159
Aaberge IS. Experience With Pneumococcal Conjugate Vaccine in Norway. Expert Rev Vaccines. 2009;8(2):159-65. PubMed PMID: 19196196.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Experience with pneumococcal conjugate vaccine in Norway. A1 - Aaberge,Ingeborg S, PY - 2009/2/7/entrez PY - 2009/2/7/pubmed PY - 2009/2/21/medline SP - 159 EP - 65 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 8 IS - 2 N2 - Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced into the Norwegian childhood vaccination program in July 2006 in a 2+1 dose (three-dose) schedule. Vaccine coverage quickly reached high levels and the incidence rate of invasive pneumococcal disease in children under 2 years of age declined rapidly. The vaccine program's effectiveness was estimated to be 74%. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/19196196/Experience_with_pneumococcal_conjugate_vaccine_in_Norway_ L2 - https://www.tandfonline.com/doi/full/10.1586/14760584.8.2.159 DB - PRIME DP - Unbound Medicine ER -